Dr. Yolanda Pina, MD

Dr. Pina practices at H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida.

Dr. Pina's NPI, 1639564040, was assigned on April 2, 2015. Dr. Pina graduated from USF Health Morsani College of Medicine in 2015. Dr. Pina holds Florida license ME140138.

Dr. Pina's primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD, at 10901 McKinley Dr, Tampa, FL 33612.

Dr. Pina's primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida. Dr. Pina is also affiliated with Moffitt Cancer Hospital. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Pina to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Pina practices, 3 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Pina's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Pina is board certified in neurology by the American Board of Psychiatry and Neurology. Dr. Pina is licensed in Florida.

Dmand AI lists carpal tunnel syndrome, encephalopathy, epilepsy, hereditary polyneuropathy, migraine and chronic headache and neuropathy among the conditions Dr. Pina treats.

CMS data shows 131 Medicare services from Dr. Pina across 2 procedure codes in 2024, all of them office visits, for 89 Medicare patients. Medicare paid $11,950 for them.

CMS counts 89 Medicare patients who saw Dr. Pina in 2024. The largest group is 65 to 74, with 42 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 16% are also on Medicaid. Their average risk score is 2.76, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Pina's median patient age at 64, with 55% women.

In 2024, Dr. Pina wrote 276 Medicare Part D claims for 61 patients. 87% of them were for generic drugs. CMS names the drug for 160 of them, across 7 drugs with 11 or more claims each, at $33,809 in total drug cost. In 2023, CMS named 72 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Pina for performance year 2024, reported as part of a group. Dr. Pina accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Pina as offering telehealth.

Dmand AI links 18 papers to Dr. Pina, published from 2010 to 2025. 2021 was the busiest year, with 3. The most frequent topics are Meningeal Neoplasms, Brain Neoplasms and Breast Neoplasms. Dr. Pina has published most often in J Neurooncol. Dr. Pina's most frequent co-authors are Peter A. Forsyth, MD, Sepideh Mokhtari, MD and Michael A. Vogelbaum, MD.

CMS Open Payments shows 10 general payments to Dr. Pina from 3 drug and device companies from 2022 to 2025. Food and beverage make up the largest share, 100% of the total. UCB, Inc. paid the most, $137.

Dr. Pina graduated from USF Health Morsani College of Medicine in 2015.

Dr. Pina is in network with 11 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.